Foot ulcer and risk of lower limb amputation or death in people with diabetes: A national population-based retrospective cohort study

Running Title: Outcomes after foot ulceration

Rosemary C Chamberlain, MPH. Department of Diabetes and Endocrinology, Ninewells Hospital, Dundee, UK

Kelly Fleetwood, MSc. Usher Institute, University of Edinburgh, Edinburgh UK

Sarah H Wild, PhD. Usher Institute, University of Edinburgh, Edinburgh, UK

Helen M Colhoun, MD. Institute of Genetics and Cancer, University of Edinburgh, UK

Robert S Lindsay, PhD. Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK

John R Petrie, PhD. Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK

Rory J McCrimmon, MD. School of Medicine, University of Dundee, UK

Fraser Gibb, PhD. Edinburgh Centre for Endocrinology and Diabetes, Royal Infirmary of Edinburgh, Edinburgh, UK

Sam Philip MD. Diabetes Centre, Aberdeen Royal Infirmary, Aberdeen, UK

Naveed Sattar, PhD. Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK

Brian Kennon, MD. Diabetes Centre, New Victoria Hospital, Glasgow, UK

Graham P Leese MD. Department of Diabetes and Endocrinology, Ninewells Hospital, Dundee, UK

Address for correspondence:

Graham Leese

Ward 5 corridor, Ninewells Hospital, Dundee, UK DD19SY

Tel: +44-1382 740471

Fax: +44=1382 425509

Email: graham.leese2@nhs.scot

Word count: Abstract 250, Total article 3992

Tables: 3, Figures: 1

Abstract

Objective

To describe incidence of foot ulceration and amputation free survival associated with foot ulceration status in a national population-based cohort study of people with diabetes.

Research Design and Methods

The study population included 233,459 people with diabetes who were alive in Scotland on 1st January 2012 identified from the national population-based register (national prevalence 4.9%). Characteristics of patients identified from linked hospital and mortality records during follow-up to the end of November 2017 were compared by outcome. Cox regression was used to assess the association between history of foot ulcer and amputation free survival.

Results

The population included 23,395 people with type-1 diabetes and 210,064 people with type-2 diabetes. In total there were 13,093 (5.6%) people with a previous foot ulceration, 9,023 people developed a first ulcer, 48,995 died and 2,866 underwent minor or major amputation during follow-up. Overall incidence of first time foot ulcers was 7.8 per 1000 person years (95% CI: 7.6-7.9) and 11.2 (11.0-11.4) for any ulcer. Risk factors for reduced amputation-free survival included social deprivation, mental illness and being underweight in addition to conventional cardiovascular risk factors. Adjusted hazards ratios (95% CI) were 2.09 (1.89-2.31) for type-1 diabetes and 1.65 (1.60-1.70) for type-2 diabetes.

Conclusion

The overall incidence of foot ulceration in a population-based study of people with diabetes was 11.2 per 1000 person years. Foot ulceration is associated with lower amputation-free survival, a potential measure of effectiveness of care among people with diabetes. Mental illness and social deprivation are also highlighted as risk factors.

Introduction

Almost half of all lower limb amputations in the UK are associated with diabetes (1). In people with diabetes, lower limb amputations are preceded by foot ulcers in approximately 85% of cases (2). Care for people who have foot ulcers and amputations requires the input of complex multi-disciplinary teams, and diabetes-related amputations are the most costly complication of diabetes (3). It is thus important to understand the epidemiology of diabetes related foot ulceration and amputations to enable accurate planning and appropriate resource allocation.

The annual incidence of any lower limb amputation has previously been reported to be between 1 and 4.5 per 1000 people with diabetes (1, 4-8). The ratio of minor:major amputation has increased from 1 (4) to over 2 (7,8) with time which may reflect declining rates of major amputation. The incidence of major amputation declined in Finland from 0.9 to 0.5 (9), Belgium from 0.4 to 0.3 (7), Germany from 0.8 to 0.6 (8), and Scotland from 1.9 to 1.1 (4) with all amputations declining in the US from 11.2 to 3.9 per 1000 person years (5). However, although decreasing rates of amputation may reflect improved care, they may also reflect delayed presentation and early death in patients with foot ulceration and/or ischemia (1,2). Thus "amputation-free survival" for patients with foot ulcers has been suggested as a useful outcome measure.

It is difficult to collect high quality epidemiological data on unbiased populations with diabetic foot ulcers. This is because the management of diabetes-related foot ulcers can take place in a large number of different community and hospital locations. To collect data from all these settings can be challenging, but to recruit from only a few of these may result in bias.

Both ulcer-specific and person-level factors influence outcomes for patients with a diabetes-related foot ulcer. In a recent review by the International Working Group for the Diabetic Foot, the main ulcer and foot-related criteria that predict poor healing of diabetes-related foot ulcers included ulcers that are large in area, deep, multiple, infected or located at the mid foot or heel, in addition to loss of protective foot sensation (10). The main patient level predictors of poor healing were reported as age, diabetes duration, male sex, renal failure, peripheral vascular disease and prior history of ulcer/amputation (10-14). More recently social deprivation (15, 16) and depression (17) have been identified as risk factors for poor outcomes in people with diabetes and foot disease.

Using population-based data which identifies people with diabetes and foot ulcers treated in community and hospital settings, we have previously reported outcomes of people in Scotland at high risk of foot ulceration, over a two year follow-up (18). In this analysis we describe foot ulcer incidence and the association of foot ulcer history and a wide variety of person-level variables with lower limb amputation or death over a longer period of follow-up.

Methods

Data sources:

This study used data from the Scottish Care information (SCI) - Diabetes data that were extracted in 2017. SCI-Diabetes is a disease-specific electronic patient record, covering more than 99% of all people with a diagnosis of diabetes in Scotland (19). It integrates demographic, clinical, biochemical and prescription data from primary and secondary care health-care information systems, downloaded daily. This dataset was linked to Scottish data regarding hospital admissions (SMR01: general/acute inpatient and day case, SMR04: mental health inpatient and day case), death records, and the Scottish Renal Registry. SMR01 and SMR04 data cover hospital discharges from 1981 onwards. International Classification of Diseases, Ninth Revision (ICD-9) codes were used to define diagnoses for discharges up to March 1996, and ICD-10 (Tenth Revision) from April 1996 to present. Office of Population Censuses and Survey (OPCS) Classification of Interventions and Procedures version 3 (OPCS-3) codes were used to record operations with discharges up to 1988 and OPCS-4 (version 4) from 1989 to present. All ICD/OPCS codes used in this study are listed in supplementary table S1. Data were linked using the unique patient identifier used for all health records in Scotland, by the electronic data research and innovation service (eDRIS) of Public Health Scotland. Approval for creation and analysis of the linked dataset was obtained from the Scotland A multi-centre research ethics committee and the Public Benefit and Privacy Panel of National Health Service Scotland.

Cohort derivation

Patients were eligible for inclusion in this study if they were recorded as being diagnosed with type-1 or 2 diabetes mellitus before 1 January 2012, were alive on this date, resident in Scotland, their records had no known data-linkage errors and they had data available on all covariates of interest. The study population comprised 233,459 people, who were followed up to 30th November 2017, the most recent date for which linked data were available (Supplementary Figure S1).

Covariate definitions

Diabetes type was assigned through an algorithm which combines clinician-recording and insulin/sulfonylurea prescription data, as described previously (20). Area-based socio-economic status was assigned using the 2012 Scottish Index of Multiple Deprivation (SIMD) at the residential address. The SIMD is an area-level index combining indicators of income, education, employment, health, access to services, housing, and crime.

History of ischemic heart disease (IHD), stroke, peripheral vascular disease (PVD) and end stage renal disease were identified using hospital records of diagnoses and relevant operations (see supplementary table 1). A dialysis record in the Scottish Renal Registry was also used as an indicator of history of end-stage renal disease. A history of mental illness was defined as having a mental health inpatient or day case admission before 1st January 2012, and/or a minimum of 90 days prescription of drugs in British National Formulary (BNF) sections 4.2 (drugs for psychosis) or 4.3 (antidepressants), with restriction of section 4.3.1 (tricyclic

antidepressants) prescriptions to those at a daily dose >50mg because lower doses are more usually used for neuropathy rather than depression.

SCI-diabetes data were used to determine smoking status, body mass index (BMI), systolic blood pressure (SBP), glycated hemoglobin (HbA1c) and cholesterol. Data from the closest time point to 1st January 2012 were used, with a 2-year maximum interval imposed for all apart from smoking status for which no maximum interval was defined. 'Never smokers' were re-classified as 'ex-smokers' if more than 15% of prior recordings were 'current' or 'ex-smoker'. BMI was classified as: underweight: <18.5 kg/m^2, normal weight: ≥18.5 and <25 kg/m^2, overweight: ≥25 and <30 kg/m^2, obese: ≥30 kg/m^2. HbA1c was categorised into three groups: <7.5% (58 mmol/mol), 7.5-9.0% (58-75 mmol/mol) and >9.0% (75 mmol/mol), reflecting national audit data categories. Prescribing data were also used to identify prescribing of anti-hypertensives in BNF section 2.5.5 (ACE Inhibitors, ARB blockers and renin inhibitors), lipid lowering therapies from BNF section 2.12 and insulin from BNF section 6.1.1.1 and 6.1.1.2. Only prescriptions for 90 days or longer were included. In the analyses, high blood pressure was defined as SBP ≥140 mmHg and/or anti-hypertensive prescription, and high cholesterol as total cholesterol >5mmol/l and/or prescription of lipid-lowering drugs.

Incidence of foot ulcers

Diabetes related foot ulcers were identified using both hospital admission (SMR01) and SCI-diabetes data. Annual foot examinations are recorded in SCI-diabetes, including records of foot ulcer status (active, previous, or none). A history of diabetes related foot ulcer at baseline was defined as any record of active or previous diabetes related foot ulcer in SCI-diabetes, from 1st January 2004 (start of national SCI-diabetes coverage) to 31st December 2011 inclusive, or any hospital admission with a diagnosis indicating diabetes related foot ulcer up to 31st December 2011. A new foot ulcer after baseline was defined as a new record between 1st January 2012 and 30th November 2017 inclusive. These dates were chosen to allow sufficient time for follow up alongside a reasonable length of time prior to baseline to reliably identify people with previous ulcers.

Lower limb amputation and death

History of prior amputation at baseline was identified using SCI-diabetes and hospital admission records. Amputations during the follow-up period were identified using hospital admissions only as more data were available on level of amputation from hospital records than from SCI-diabetes. Amputation below the ankle was defined as minor, and above the ankle was defined as major. Where minor and major amputations were recorded within a single hospital admission, only the major amputation was counted. Traumatic amputation and amputations prior to diagnosis of diabetes were excluded. Deaths and date of death were identified from linked Scottish death records.

Analysis methods

Descriptive tables

The distribution of baseline variables were compared between people in the study population who underwent amputation or death during follow-up and those who survived to the end of follow-up without having an amputation using chi-squared tests.

Time to event analysis

The outcomes of interest were incidence of ulcers during follow up and lower limb amputation (major or minor) and death. Kaplan-Meier curves were plotted to show the probability of amputation-free survival across the follow-up period, in the groups with and without history of foot ulcer at baseline.

Cox regression models were used to compare the hazards of amputation/death between the groups by foot ulcer status. Time to event was defined as the time from 1st January 2012 to the earliest date of first amputation (major or minor) in the follow-up period, or date of death, with censoring at the end of the study period (30 November 2017). A univariable model for history of foot ulcer was fitted first, followed by multivariable models to adjust incrementally for further variables. The first multivariable model adjusted for demographic data such as age, sex, socioeconomic deprivation (as measured by quintiles of SIMD 2012) and diabetes duration (as categorised in Table 2). The second added further adjustment for pre-baseline amputation history, the third added further adjustment for history of pre-existing conditions, namely stroke, IHD, PVD, end-stage renal failure and mental illness, whilst the fourth added further adjustment for metabolic risk factors namely BMI, HbA1c, insulin prescription (Type-2 diabetes only), smoking, high blood pressure and high cholesterol. The fifth model additionally adjusted for the time varying ulcer status during follow up by allowing patients who were in the 'no ulcer history' group at baseline to move into the ulcer history group at the time point at which their first ulcer was recorded. We assessed the proportional hazards assumption using plots of log(-log(amputation-free survival probability)) against time (supplementary Figure S2) and found no evidence of violation of the assumption.

All results were stratified by diabetes type because there was a statistically significant interaction between type of diabetes and history of foot ulcer in the fully adjusted multivariable model.

All analyses were conducted in R version 3.6.0.

RESULTS

The study population of 233,459 people reflects 89.4% of 261,215 potentially eligible individuals after excluding 27,756 people with missing data for one or more covariate (Suppl Fig 1). During follow up to 30th November 2017, 9,023 (4.1%) people with no foot ulcer at baseline developed new ulcers. Of people who had a foot ulcer prior to baseline, 4,495 (34.3%) developed a further foot ulcer during follow up. The incidence of first time foot ulcers was 7.8 per 1000 person years follow up (95% CI: 7.6-7.9) and the rate of recurrent ulceration was 97 per 1000 person years (95% CI: 94-99). For all patients there was an incidence of a new or recurrent ulcer of 11.2 per 1000 person years (11.0-11.4).

The numbers of people with outcomes of interest by type of diabetes and foot ulcer history are shown in Table 1. In total 50,696 people had 51,861 events. Overall, 21.7% of the cohort had an amputation or died during follow up, with a higher proportion among people with a previous history of foot ulcer compared to those with no history of foot ulcer. For type-1 diabetes there were 2,506 (10.7% of the population) events, with 9.3% dying and 2.1% undergoing an amputation. For type-2 diabetes there were 48,190 (22.9% of the population) events with 22.3% dying and 1.1% undergoing an amputation (some died after an amputation).

For people without a history of foot ulcers there were 44,214 (20.1% of the population) events, with 43,175 deaths (19.6%) and 1,638 amputations (0.7%). For people with a history of an ulcer there were 6,482 (49.5% of the population) events, with 5,820 deaths (44.5%) and 1228 amputations (9.4%).

For people with type-1 diabetes who reached an end point (amputation or death), 12.9% and 33.9% had an amputation for those with no history of an ulcer and those with a previous ulcer respectively (Table 1). The proportions were similar between minor and major amputations. Proportions for type-2 diabetes were much lower, at 3.3% and 16.9% for those without and with previous foot ulcers respectively. There was a similar equal split between minor and major amputations.

The characteristics of patients with type-1 and type-2 diabetes who had an amputation or died are compared to those with amputation-free survival in Table 2. The following baseline characteristics were associated with increased risk of death or amputation: male sex (type-1 diabetes only), increasing age, increasing duration of diabetes, end-stage renal failure, history of IHD, PVD, stroke, previous foot ulcer, history of amputation, and cardiovascular risk factors such as current/ex-smoker, hypertension and high cholesterol. Differences in distributions of all above characteristics were statistically significant by outcome status ($P<0.0001$). Social deprivation and mental illness were also associated with increased risk of death or amputation ($P<0.0001$), especially in type-1 diabetes. For social deprivation the crude risks were 1.9-fold higher in the most compared to least deprived quintiles in type-1 diabetes, and 1.2-fold higher in type-2 diabetes. The crude risk of death or amputation was 1.7-fold and 1.1-fold higher for those with mental illness in type-1 and type-2 diabetes respectively, compared to those without mental illness.

In both type-1 and type-2 diabetes, low BMI was associated with death or amputation (Table 2). For both diabetes types there was an apparent U-shaped association for HbA1c and outcome.

Kapan Meier curves show the reduced probability of amputation-free survival among patients with a history of foot ulcer (Fig.1) compared to people without a history of foot ulcer at baseline. Cox-regression hazard ratios for history of foot ulcer from univariable and multivariable models were higher for type-1 than type-2 diabetes and were attenuated by increasing adjustments but remained statistically significant (Table 3). Results stratified by sex did not show substantial differences to the overall findings (not shown).

DISCUSSION

During a potential duration of six years follow-up 21.7% of the whole study population died or had an amputation. Death was a more common outcome than amputation, both for people with and without a history of foot ulcer at baseline. Amputation or death occurred for approximately 1 in 2 of those with a prior foot ulcer and 1 in 5 with no previous foot ulcer. The univariable HR of amputation or death for those with a history of foot ulcer history at baseline was 5.43 (95%CI 4.98-5.91) for type-1 diabetes and 3.12 (95%CI 3.03-3.21) for type-2 diabetes. Overall type-1 diabetes is a risk factor for adverse outcomes in people with a history of a foot ulcer. After adjusting for all variables such as diabetes duration, presence of macrovascular and microvascular disease, HbA1c and vascular risk factors, there remains a significant difference (Table 3). As expected, death and amputations were more common in those with existing vascular disease and end-stage kidney disease, and also those with established cardiovascular risk factors, increased age, longer diabetes duration and previous amputations. In addition, higher risk of death or amputation was associated with living in more socially deprived areas, mental illness and being underweight (BMI <18.5 kg/m^2). Higher proportions of people with an HbA1c <7.5% (58mmol/mol) or >9.0% (75mmol/mol) died or had an amputation compared to those in the mid-range (58-75 mmol/mol).

We have previously reported 76% amputation free survival after 2 years among people with diabetes who were at high risk of foot disease, defined as having multiple risk factors (e.g. neuropathy and vascular disease) or prior ulceration (18). In this analysis, for people with diabetes and a foot ulcer prior to baseline, 50% were free of amputation during a maximum of 5.9 years of follow up (48% of those with type-2 diabetes and 63% of those with type-1 diabetes).

Overall survival during follow-up for those with a history of ulcer was 56% (type-1 diabetes: 71%, type-2 diabetes: 53%) in our cohort, which compares with five year survival of 56-78% in other studies (21-27). Higher proportions survived in studies that excluded people with prior ulcer or peripheral vascular disease (22) or first time attenders at a foot clinic, which will exclude many people with recurrent ulcers (23).

People who have diabetes and a prior foot ulcer are reported to have a crude 4-fold increased mortality at a median of 3.6 years (28), a 2.5-fold increased risk at 5 years (21) and a 1.5-fold increased risk at 10 years follow-up (29) compared to patients with diabetes and no history of foot ulcer. Our findings of a crude 2.3-fold increased mortality during 5.9 year follow-up for those with prior foot ulcer compared to those without are consistent with previous estimates.

Our findings reaffirm that previous myocardial infarction, stroke and PVD, in addition to chronic kidney disease are associated with higher risks for death/amputation (10,21,24). In addition we have demonstrated that social deprivation and mental illness are also associated with poor outcomes. This was particularly notable for type-1 diabetes. Social deprivation has been associated with the onset of foot ulceration (15,16, 30). In one study of 1147 people with type-2 diabetes, the risk of early mortality in those who developed foot ulceration increased by 14% per quintile of deprivation in univariable analysis (30). Factors mediating

the effect of social deprivation may include reduced access to and/or use of, health-care resources, reduced health literacy, poorer nutrition and housing. In other populations that are more racially diverse, race and racial inequality are also likely to contribute to adverse outcomes (31). A previous meta-analysis showed that depression was associated with a 1.7-fold increased risk of amputation (17), and increased risk of premature death after amputation in people with diabetes (32).

We identified an association of death or amputation and low BMI that was particularly marked for people with type-2 diabetes. Those having a BMI under 18.5kg/m^2 had twice the risk of amputation/death compared to those with a normal BMI. This has been noted in previous studies (33) and was independent of factors such as chronic kidney disease or cardiovascular disease. Low BMI may be due to known or undiagnosed malignancy, and there is likely to be residual confounding from inaccurate measurement of smoking. However it is also likely to reflect under-nutrition and sarcopenia, which is a known risk factor for death in those who have had an amputation (34) and is a likely cause of foot ulceration (35) due to loss of foot plantar fat pads and muscle wasting.

An additional intriguing factor is the association of low HbA1c (in addition to high HbA1c) and adverse outcomes which has also been reported elsewhere (21). Although shown to be an additional independent risk factor, low HbA1c may partly be attributed to poor nutrition, malignancy and frailty. Poor nutrition and / or frailty or co-existing disease can be associated with lower HbA1c and increased risk of death and amputation, giving a possible element of reverse causality. However, the increased risk of amputation/mortality associated with foot ulcer remained evident after adjusting for HbA1c and BMI indicating that they do not fully explain the association.

We report overall incidence of any new or recurrent foot ulcer between 2012 and 2017 of 11.2 per 1000 person years. This rate is lower than the range of 2-6% for combined incident and recurrent ulcers (11,12,36-38) reported in publications more than five years ago. First time foot ulcer incidence of <1% has been reported recently (30). The estimated incidence of any ulcer derived from a large community Dutch study was 1.1% when the study population was limited to people whose foot status was known for certain (39). These larger population-based studies seem to report a lower incidence of ulceration than from smaller selected populations (11,12, 36-38). An alternative explanation for the discrepancy between these studies is that the incidence of foot ulceration may have decreased in European populations in the last 15-20 years. Despite a decreasing incidence, the increasing prevalence of diabetes as a consequence of increasing survival (40), can be expected to result in larger absolute numbers of people with foot ulcers and increasing costs of treatment. Lifetime incidence of foot ulcers has been estimated to be 15% or more using a predefined formula (38). Using the same formula for our data, results in a marginally lower rate of 11.5% (1 in 8 people).

Limitations of this study include the possibility of underestimating the number of people with foot ulcers in the cohort. This is likely to have resulted in underestimating the differences between those recorded with ulcers compared to those without, especially in terms of the

outcome of death or amputation. This may also have resulted in an underestimate of the population incidence of foot ulceration. Recording of some of the events of associated conditions (e.g. in Table 2), depended on an inpatient episode and thus may have missed outpatient episodes such as for people with transient ischemic attack or angina. This may have resulted in an under diagnosis of stroke, PVD and IHD but this is unlikely to have differed between those with and without baseline foot ulceration. Further limitations include lack of data on foot ulcer characteristics, anemia or other biochemical data and the use of a single baseline measure of covariates, some of which may have changed during follow up, likely resulting in bias towards the null. Approximately 10% of the study population had missing data for one or more variables with the largest proportions of missing data for baseline BMI, deprivation and HbA1c. Proportions of people who received an amputation or who died were similar in the group excluded for having missing data to those among the study population. However, the national scale of the dataset is a major strength.

In conclusion, these national data with almost six years of follow-up demonstrated a strong association between a history of foot ulcer and amputation or death. In addition to standard risk factors, several variables including social deprivation, mental illness, low BMI and low HbA1c were associated with poor outcomes. Factors including social deprivation, mental illness and vascular risk factors need to be addressed in order to reduce premature mortality and amputations for people with diabetes and foot ulcers.

Acknowledgements

None of the authors have a conflict of interest

These data were available for analysis by members of the Scottish Diabetes Research Network Epidemiology group thanks to the hard work of numerous people and organisations (staff in each Health Board, the SCI-diabetes Steering Group, the Scottish Diabetes Group, the Scottish Diabetes Survey Group, the managed clinical networks managers and at the Information Services Division of NHS National Services Scotland) involved in providing data, setting up, maintaining and overseeing SCI-diabetes and other linked databases. We acknowledge the support of the Diabetes Epidemiology Group at the University of Edinburgh for managing research data. We acknowledge the financial support of NHS Research Scotland (NRS), through Diabetes Network for data linkage.

Contributions

RC and KF undertook the data curation the formal analysis and helped write the manuscript. GL and SW designed the study wrote the protocol, had overview of the analysis, were supervisors and wrote the original manuscript. HC, RL, JP, RM, FG, SP, NS, BK were involved in the methodology, reviewed the study design and contributed to the revision of the manuscript.

Conflict of Interest

None of the authors have a conflict of interest

Funding

This study was funded by NHS Tayside research endowments

Guarantor

Professor Graham Leese is the guarantor

References

1. Holman N, Young RJ, Jeffcoate WJ. Variation in the recorded incidence of amputation of the lower limb in England. Diabetologia. 2012; 55: 1919-1925

2. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. The Lancet.2003; 361: 1545-1551.

3. Barshes NR, Sigireddi M, Wrobel JS, Mahankali A, Robbins JM, Kougias P, Armstrong DG. The system of care for the diabetic foot: objectives, outcomes, and opportunities. Diabet Foot Ankle. 2013; 10: ;4. doi: 10.3402/dfa.v4i0.21847

4. Kennon B, Leese GP, Cochrane L, Colhoun H, Wild S, Stang D, Sattar N, Pearson D, Lindsay RS, Morris AD, Livingstone S, Young M, McKnight J, Cunningham S. Reduced incidence of lower extremity amputations in people with diabetes in Scotland: a nationwide study. Diab Care 2012; 35: 2588-2590

5. Li Y, Burrows NR, Gregg EW, Alrbright A, Geiss LS. Declining rates of hospitalization for non-traumatic lower-extremity amputation in the diabetic population aged 40 years or older: US, 1988-2008. Diabetes Care 2012; 35: 273-277

6. Margolis DJ, Hoffstad O, Weibe DJ. Lower-extremity amputation risk is associated with variation in behavioral risk factor surveillance system responses. Diabetes Care. 2014; 37: 2296-301

7. Claessen H, Avalosse H, Guillaume J, Narres M, Kvitkina T, Arend W, Morbach S, Lauwers. P, Nobels F, Boly J, Van Hul C, Doggen K, Dumont I, Felix P, Van Acker K, Icks A. Decreasing rates of major lower-extremity amputation in people with diabetes but not in those without: a nationwide study in Belgium. Diabetologia 2018; 61: 1966-1977.

8. Claessen H, Narres M, Haastert B, Arend W, Hoffman F, Morbach S, Rumenapf G, Kvitkina T, Friedel H, Gunster C, Schubert I, Ullrich W, Westerhoff B, Wilk A, Icks A. Lower-extremity amputations in people with and without diabetes in Germany, 2008-2012 - an analysis of more than 30 million inhabitants. Clin Epidemiol 2018; 10: 475-488.

9. Ikonen TS, Sund R, Venermo M, Winell K. Fewer major amputations among individuals with diabetes in Finland in 1997-2007: a population-based study. Diabetes Care. 2010;33:2598-603.

10. Monteiro-Soares M, Russell D, Boyko EJ, Jeffcoate W, Mills JL, Morbach S, Game F. International Working Group on the Diabetic Foot (IWGDF) Guidelines on the classification of diabetic foot ulcers (IWGDF 2019). Diabetes Metab Res Rev 2020; 36 Suppl 1:e3273

11. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ERE, Whalley AM, Widdows P, Williamson S, Boulton AJM. The North West Diabetes Care Foot study: incidence of,

risk factors for, new diabetic foot ulceration in a community-based cohort. Diab Med 2002; 19: 377-84

12. Boyko EJ, Ahoroni JH, Cohen V, Nelson KM, Heagerty PJ. Prediction of diabetic foot ulcer occurrence using commonly available clinical information. Diab Care 2006; 29: 1202-1207

13. Monteiro-Soares M, Boyko EJ, Ribeiro J, Ribeiro I, Dinis-Ribeiro M. Predictive factors for diabetic foot ulceration: a systematic review Diabetes Metab Res Rev 2012; 28: 574-600.

14. Crawford F, Cezard G, Chappell FM, Murray GD, Price JF, Sheikh A, Simpson CR, Stansby GP, Young MJ. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS) Health Technol Assess . 2015; 19: 1-210

15. Leese GP, Feng Z, Leese RM, Dibben C, Emslie-Smith A Impact of healthcare accessibility and social deprivation on diabetic foot disease. Diab Med 2013; 30: 484-90

16. Hurst JE, Barn R, Gibson L, Innes H, Bus SA, Kennon B, Wylie D, Woodburn J. Geospatial mapping and data linkage uncovers variability in outcomes of foot disease according to multiple deprivation: a population cohort study of people with diabetes Diabetologia . 2020; 63: 659-667.

17. O'Neil SM, Kabir Z, McNamara G, Buckley CM. Comorbid depression and risk of lower extremity amputation in people with diabetes: systematic review and meta-analysis BMJ Open Diabetes Res Care . 2017; 5(1): e000366. doi: 10.1136/bmjdrc-2016-000366.

18. Vadiveloo T, Jeffcoate W, Donnan PT, Colhoun HC, McGurnaghan S, Wild S, McCrimmon R, Leese GP Amputation free survival in 17,353 people identified as being at high risk from feet disease in diabetes: A National observational study. Diabetologia 2018; 61: 2590 - 2597

19. Anwar H, Fischbacher CM, Leese GP, Lindsay RS, McKnight JA, Wild SH, Assessment of the under-reporting of diabetes in hospital admission data: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabet Med. 2011; 28: 1514-9.

20. Read SH, Kerssens JJ, McAllister DA, Colhoun HM, Fischbacher CM, Lindsay RS, McCrimmon RJ, McKnight JA, Petrie JR, Sattar N, Wild SH Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia 2016; 59: 2106-13.

21. Walsh, JW, Hoffstad OJ, Sullivan MO, Margolis DJ. Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med 2016; 33: 1493-1498.

22. Rastogi A, Goyal G, Kesavan R, Bal A, Kumar H, Mangalanadanam, Kamath P, Jude EB, Armstrong DG, Bhansali A. Long term outcomes after incident diabetic foot ulcer: Multicenter large cohort prospective study (EDI-FOCUS investigators) epidemiology of diabetic foot complications study: Epidemiology of diabetic foot complications study. Diabetes Res Clin Pract. 2020; 162:108113. doi: 10.1016/j.diabres.2020.108113

23. Jeyaraman K, Berhane T, Hamilton M, Chanda AP, Falhammar H. Mortality in patients with diabetic foot ulcer: a retrospective study of 513 cases from a single Centre in the Northern Territory of Australia. BMC Endocr Disord. 2019; 19: 1. doi: 10.1186/s12902-018-0327-2.

24. Rubio JA, Jiminez S, Lazaro-Martinez JL. Mortality in Patients with Diabetic Foot Ulcers: Causes, Risk Factors, and Their Association with Evolution and Severity of Ulcer. J Clin Med. 2020; 9: E3009. doi: 10.3390/jcm9093009.

25. Morbach S, Furchert H, Groblinghoff U, Hoffmeier H, Kersten K, Klauke G, Klemp U, Roden T, Icks A, Haasert B, Rumenapf G, Abbas ZA, Bharara M, Armstrong DG. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diab Care 2012; 35: 2021-7.

26. Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer J Foot Ankle Res. 2020; 13:16. doi: 10.1186/s13047-020-00383-2.

27. Jupiter DC, Thorud JC, Buckley CJ, Shibuya N. The impact of foot ulceration and amputation on mortality in diabetic patients. I: From ulceration to death, a systematic review Int Wound J . 2016; 13:892-903.

28.Brownrigg, JR, Griffin M, Hughes CO, Jones KG, Patel N, Thompson MM, Hinchliffe RJ. Influence of foot ulceration on cause-specific mortality in patients with diabetes mellitus. J Vasc Surg 2014; 60: 982-986.

29. Iversen MM, Tell GS, Riise T, Hanestad BR, Østbye T, Graue M, Midthjell K. History of foot ulcer increases mortality among individuals with diabetes: ten-year follow-up of the Nord-Trøndelag Health Study, Norway Diabetes Care 2009; 32 :2193-9.

30. Anderson SG, Shoo H, Saluja S, Anderson CD, Khan A, Livingston M, Jude EB, Lunt M, Dunn G, Heald AH. Social deprivation modifies the association between incident foot ulceration and mortality in type 1 and type 2 diabetes: a longitudinal study of a primary-care cohort. Diabetologia. 2018; 61: 959-967.

31. Mizelle RM. Diabetes, race and amputations. The Lancet 2021; 397: 1256-7

32. Cascini S, Agabiti N, Davoli M, Uccioli L, Meloni M, Giurato L, Marino C, Baragagli AM. Survival and factors predicting mortality after major and minor lower-extremity amputations among patients with diabetes: a population-based study using health information systems. BMJ Open Diab Res Care. 2020; 8: e001355

33. Gazzaruso C, Gallotti P, Pujia A, Montalcini T, Giustina A, Coppola A. Predictors of healing, ulcer recurrence and persistence, amputation and mortality in type 2 diabetic patients with diabetic foot: a 10-year retrospective cohort study Endocrine. 2021; 71: 59-68

34. Kim YK, Lee HS, Ryu JJ, Lee HI, Seo SG. Sarcopaenia increases the risk for mortality in patients who undergo amputation for diabetic foot. J Foot Ankle Res 2018; 11: 32

35. Haughey L, Barbul A. Nutrition and lower extremity ulcers: casuality and/or treatment. In J Low Extrem Wounds 2017; 16: 238-243

36. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH. Incidence, outcomes and cost of ulcers in patients with diabetes Diabetes Care, 1999; 22: 382-387

37. Muller IS, DeGraw WJ, van Gerwen WH , Bartelink ML, van Den Hoogen HJM, Rutten GEHM. Foot ulceration and lower limb amputation in type 2 diabetic patients in Dutch primary care Diabetes Care, 2002: 25; 570-574

38. Armstrong DG, Boulton AJ, Bus SA. Diabetic foot ulcers and their recurrence. New England Journal of Medicine. 2017; 376: 2367-75.

39. Stoekenbroek RM, Lokin JLC, Nielen MM, Stroes ESG, Koelemay MJW. How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population. Diabetologia. 2017; 60: 1271-1275.

40. Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon RJ, Metcalfe W, McKnight JA, Morris AD, Pearson DWM, Petrie JR, Philip S, Sattar NA, Traynor JP, Colhoun HM. Estimated life expectancy in a Scottish Cohort with diabetes, 2008-2010. JAMA 2015; 313: 37-44

Table 1. Numbers of ulcers, lower limb amputations and deaths in the study population of people with diabetes in Scotland by foot ulcer history at 01/01/12 and type of diabetes (p<0.001 for all comparisons by ulcer history).

TYPE-1 DIABETES	No History of Ulcer (N=21290)	History of Ulcer (N=2105)
Foot ulcer during follow up	998	826
	Final Outcomes* (Proportion of all amputations and deaths %)	**Final Outcomes* (Proportion of all amputations and deaths %)**
Amputation or death	1736	770
Death	1569 (90.4)	615 (79.9)
Amputation (any)	224 (12.9)	261(33.9)
Major amputation	110 (6.3)	145 (18.8)
Minor amputation	137 7.9)	156 (20.3)
TYPE-2 DIABETES	No History of Ulcer (N=199076)	History of Ulcer (N=10988)
Foot ulcer during follow up	8025	3669
	Final Outcomes* (Proportion of all amputations and deaths %)	**Final Outcomes* (Proportion of all amputations and deaths %)**
Amputation or death	42478	5712
Death	41606 (97.9)	5205 (91.1)
Amputation (any)	1414 (3.3)	967 (16.9)
Major amputation	748 (1.8)	538 (9.4)
Minor amputation	831 (2.0)	579 (10.1)

*Some patients had minor and major amputations. Some patients had amputations and then died. Thus the sum of the percentages is greater than 100%.

Table 2: Characteristics of study population of people with diabetes in Scotland in 2012 by outcome of amputation or death during follow-up to 2017, stratified by type of diabetes. Differences in criteria were all statistically significant (p<0.0001) between those who survived without amputation and those who did not, for both type-1 and type-2 diabetes.

	Type-1 Diabetes	**Type-1 Diabetes**	**Type-2 Diabetes**	**Type-2 Diabetes**
CRITERION	**Amputation free survival (N=20889)**	**Amputation or death (N=2506)**	**Amputation free survival (N=161874)**	**Amputation or death (N=48190)**
Sex				
Female	9241 (90.3%)	994 (9.7%)	71629 (76.5%)	21992 (23.5%)
Male	11648 (88.5%)	1512 (11.5%)	90245 (77.5%)	26198 (22.5%)
Age, years				
<55	16237 (94.6%)	919 (5.4%)	38701 (94.9%)	2071 (5.1%)
≥55 and <65	2905 (85.0%)	513 (15.0%)	46772 (89.0%)	5793 (11.0%)
≥65 and <75	1317 (69.4%)	580 (30.6%)	48209 (78.5%)	13202 (21.5%)
≥75	430 (46.5%)	494 (53.5%)	28192 (51.0%)	27124 (49.0%)
Diabetes duration, years				
<5	3133 (91.8%)	280 (8.2%)	69394 (84.6%)	12663 (15.4%)
≥5, <10	3212 (93.0%)	240 (7.0%)	50460 (77.8%)	14389 (22.2%)
≥10	14544 (88.0%)	1986 (12.0%)	42020 (66.5%)	21138 (33.5%)
SIMD2012 quintile				
Q1 (most deprived)	4312 (86.4%)	677 (13.6%)	37862 (75.3%)	12435 (24.7%)
Q2	4264 (87.4%)	613 (12.6%)	36993 (76.5%)	11390 (23.5%)
Q3	4383 (89.8%)	496 (10.2%)	32825 (77.5%)	9510 (22.5%)
Q4	4011 (90.7%)	413 (9.3%)	29436 (77.6%)	8498 (22.4%)
Q5	3919 (92.7%)	307 (7.3%)	24758 (79.6%)	6357 (20.4%)
End-stage renal failure				
No	20767 (89.8%)	2352 (10.2%)	161253 (77.3%)	47408 (22.7%)
Yes	122 (44.2%)	154 (55.8%)	621 (44.3%)	782 (55.7%)
IHD history				
No	19738 (91.8%)	1758 (8.2%)	132493 (81.2%)	30626 (18.8%)
Yes	1151 (60.6%)	748 (39.4%)	29381 (62.6%)	17564 (37.4%)
Stroke history				
No	20638 (89.9%)	2331 (10.1%)	157048 (78.2%)	43877 (21.8%)
Yes	251 (58.9%)	175 (41.1%)	4826 (52.8%)	4313 (47.2%)
PVD history				
No	20573 (90.7%)	2119 (9.3%)	158203 (78.4%)	43696 (21.6%)
Yes	316 (45.0%)	387 (55.0%)	3671 (45.0%)	4494 (55.0%)
History of foot ulcer at baseline				

No	19554 (91.8%)	1736 (8.2%)	156598 (78.7%)	42478 (21.3%)
Yes	1335 (63.4%)	770 (36.6%)	5276 (48.0%)	5712 (52.0%)
Smoking status				
Never smoked	10515 (93.7%)	706 (6.3%)	62908 (81.8%)	13955 (18.2%)
Ex-smoker	5519 (84.7%)	998 (15.3%)	69835 (73.6%)	24987 (26.4%)
Current smoker	4855 (85.8%)	802 (14.2%)	29131 (75.9%)	9248 (24.1%)
BMI category				
Underweight	436 (83.5%)	86 (16.5%)	361 (28.7%)	895 (71.3%)
Normal	7452 (89.5%)	873 (10.5%)	16300 (60.3%)	10719 (39.7%)
Overweight	7792 (90.7%)	802 (9.3%)	50345 (75.5%)	16372 (24.5%)
Obese	5209 (87.5%)	745 (12.5%)	94868 (82.4%)	20204 (17.6%)
HbA1c % (mmol/mol)				
<7.5% (58 mmol/mol)	3766 (88.5%)	490 (11.5%)	95707 (76.0%)	30189 (24.0%)
7.5-9.0% (58-75 mmol/mol)	8839 (90.9%)	881 (9.1%)	41764 (79.3%)	10886 (20.7%)
>9.0% (75 mmol/mol)	8284 (87.9%)	1135 (12.1%)	24403 (77.4%)	7115 (22.6%)
High blood pressure				
No	11352 (95.6%)	522 (4.4%)	40375 (83.9%)	7742 (16.1%)
Yes	9537 (82.8%)	1984 (17.2%)	121499 (75.0%)	40448 (25.0%)
High cholesterol				
No	11301 (95.4%)	544 (4.6%)	30423 (81.5%)	6920 (18.5%)
Yes	9588 (83.0%)	1962 (17.0%)	131451 (76.1%)	41270 (23.9%)
Insulin prescription				
No	n/a	n/a	146131 (78.4%)	40228 (21.6%)
Yes	n/a	n/a	15743 (66.4%)	7962 (33.6%)
Mental illness				
No	16150 (91.0%)	1602 (9.0%)	121634 (77.6%)	35113 (22.4%)
Yes	4739 (84.0%)	904 (16.0%)	40240 (75.5%)	13077 (24.5%)
Previous amputation				
No	20737 (90.1%)	2279 (9.9%)	161192 (77.4%)	46933 (22.6%)
Yes	152 (40.1%)	227 (59.9%)	682 (35.2%)	1257 (64.8%)

Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; IHD, ischemic heart disease; PVD, peripheral vascular disease; Q, quintile; SIMD, Scottish Index of Multiple Deprivation

Table 3: Univariable and adjusted hazard ratios for the association of ulcer status with amputation or death by 2017 by type of diabetes in the study population of people with diabetes in Scotland in 2012.

	Type-1 diabetes (n=23,395)	Type-2 diabetes (n=210,064)
Univariable HR (95% CI)	5.43 (4.98-5.91)	3.12 (3.03-3.21)
Multivariable model 1	3.06 (2.79-3.34)	2.13 (2.07-2.19)
Multivariable model 2	2.61 (2.36-2.88)	1.94 (1.88-2.00)
Multivariable model 3	2.19 (1.98-2.42)	1.71 (1.66-1.76)
Multivariable model 4	2.09 (1.89-2.31)	1.65 (1.60-1.70)
Multivariable model 5	3.39 (3.10-3.71)	2.42 (2.36-2.48)

Footnotes

Multivariable model 1: Ulcer history, age, sex, deprivation, diabetes duration (demographic data).

Multivariable model 2: Previous amputation, in addition to model 2 covariates.

Multivariable model 3: History of stroke, IHD, PVD, end-stage renal failure and mental illness, in addition to model 3 covariates (co-morbidities).

Multivariable model 4: BMI, HbA1c, smoking, high blood pressure, high cholesterol and insulin (Type-2 diabetes only), in addition to model 4 covariates (clinical markers).

Multivariable model 5: Time varying ulcer status during follow-up in addition to model 4.

Figure Legends

Figure 1: Kaplan Meier curves for amputation-free survival by history of foot ulcer at baseline



Abbreviations: HFU, History of foot ulcer at baseline.